GlassScriptPhysician profile
Kayla Juszczyk
NPI 1255956934
$5,037.85
in general payments reported to CMS, 2019-2025
24 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $389 · 2023: $315 · 2024: $2,542 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,274 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,274.03 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,530.25 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $739.69 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $454.78 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.82 | 2021-2025 | Jardiance |
| Pfizer INC. | $350.15 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $258.95 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $250.15 | 2024-2025 | Xifaxan, Trulance |
| Abbvie INC. | $219.99 | 2024-2025 | |
| Amgen INC. | $119.30 | 2024-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $96.17 | 2024-2025 | |
| Lundbeck LLC | $89.86 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.70 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $74.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $72.39 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $66.08 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $59.20 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $35.21 | 2024-2025 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $33.84 | 2024 | Austedo Xr, Ajovy |
| Sumitomo Pharma America, INC. | $29.53 | 2024 | Gemtesa |
| Ucb, INC. | $27.39 | 2024 | Bimzelx |
| Scpharmaceuticals INC. | $19.40 | 2025 | |
| Idorsia Pharmaceuticals US INC | $19.25 | 2024 | Quviviq |
| Tactile Systems Technology INC | $19.15 | 2025 | Nimbl, Flexitouch Plus |
| Otsuka America Pharmaceutical, INC. | $15.37 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Juszczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.